KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.95

The Value of Ultrasound in Patients with T1-T2 Breast Cancer with No Palpable Lymph Nodes Enrolled in the EORTC 10981-22023 AMAROS Trial.

A W J Beerthuizen, T I M Snellen, S A Bartels, A Kuijer, C Poncet, C A Drukker, E J T Rutgers, M J T F D Vrancken Peeters, F H van Duijnhoven

Ann Surg Oncol 33(4) 3293-3301

PMID41392224
PMCID-
DOI10.1245/s10434-025-18833-1
发表日期2025-12-14
入排依据:This is a secondary analysis from a Phase III randomized trial (AMAROS) focused on a diagnostic/procedural intervention (axillary ultrasound) and surgical management (ALND vs. ART). It does not evaluate a drug-containing intervention and does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR.
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: The use of axillary ultrasound (AUS) in breast cancer staging varies across international guidelines, ranging from routine use to targeted implementation. This study evaluates the clinical utility of AUS in patients enrolled in the AMAROS trial. METHODS: Between 2001 and 2010, patients with early-stage breast cancer (cT1-T2N0M0) were enrolled in the European Organisation for Research and Treatment of Cancer (EORTC) phase III non-inferiority AMAROS trial by 34 European sites. cN0 status was determined either by clinical examination (w/oAUS) or AUS. All patients underwent sentinel lymph node biopsy (SLNB); those with tumor-positive SLNB (SLNB+) were randomized to axillary lymph node dissection (ALND) and axillary radiotherapy (ART). RESULTS: In total, 4806 patients were included, of which 1425 SLNB+ patients were randomized. AUS was performed in 3020 (63%) patients. No differences in SLNB results between AUS groups were observed; a positive SLNB was found in 30% of AUS patients and in 32% of w/oAUS patients (p = 0.266). For the SLNB+ patients randomized in the AMAROS trial (n = 1425), baseline characteristics were comparable, except for a significantly higher number of AUS patients in the trial enrollment years between 2006 and 2010 (63%) compared with 2001-2005 (38%) (p < 0.001). Axillary tumor load did not differ between AUS groups (p = 0.156). CONCLUSIONS: In patients with cT1-2 breast cancer included in the AMAROS trial, sentinel lymph node involvement did not differ between patients who received pre-operative staging with AUS and those who were staged with clinical examination only.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。